IMPORTANT ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Clovis Oncology, Inc. and Strongly Encourages Investors to Contact the Firm

LOS ANGELES--()--Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Clovis Oncology, Inc. (“Clovis” or the “Company”) (NASDAQ: CLVS). Investors who purchased or otherwise acquired shares between October 31, 2013 and November 13, 2015, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the January 19, 2016, lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the complaint, the Company made misleading statements to investors and/or failed to disclose that: (a) the New Drug Application (“NDA”) that Clovis submitted to the FDA for rociletinib contained immature data sets; (b) Clovis’ Breakthrough Therapy designation submission contained immature data set based primarily on unconfirmed responses; (c) Clovis presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses; (d) as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected; (e) as a result of the foregoing, Clovis’ NDA was likely to be delayed and/or rejected by the FDA; and (f) Clovis was in possession of data during its third-quarter conference call held on November 5, 2015, which demonstrated that the confirmed rociletinib response rate is lower than what was previously disclosed.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, via email at info@goldberglawpc.com, or visit our website at Goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Goldberg Law PC, Los Angeles
Michael Goldberg, Esq. 800-977-7401
Brian Schall, Esq. 800-977-7401
info@goldberglawpc.com
Goldberglawpc.com

Contacts

Goldberg Law PC, Los Angeles
Michael Goldberg, Esq. 800-977-7401
Brian Schall, Esq. 800-977-7401
info@goldberglawpc.com
Goldberglawpc.com